口服糖尿病药物联合治疗降低糖化血红蛋白的疗效比较。
Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin.
机构信息
Weill Cornell Medical College, 525 East 68th Street, Baker Pavilion 20th Floor, NY 10021, USA.
出版信息
J Comp Eff Res. 2014 Jan;3(1):29-39. doi: 10.2217/cer.13.87.
Abstract
AIMS
To provide evidence on the comparative effectiveness of oral diabetes drug combinations.
METHODS
We performed a retrospective, observational cohort study of glycosylated hemoglobin change in outpatients newly exposed to dual- or triple-drug oral diabetes treatment.
RESULTS
Adjusted response to a second drug added to metformin ranged from 0.85 to 1.21% glycosylated hemoglobin decline. Response to a third drug was smaller (0.53-0.91%). Higher baseline glycosylated hemoglobin was associated with larger response; sulfonylurea effectiveness declined over time; and thiazolidinediones were more effective in obese patients and women.
CONCLUSION
Observational data provide results qualitatively consistent with the limited available randomized data on diabetes drug effectiveness, and extend these findings into common clinical scenarios where randomized data are unavailable. Sex and BMI influence the comparative effectiveness of diabetes drug combinations.
摘要
目的
提供口服糖尿病药物联合治疗比较效果的证据。
方法
我们对新接受二甲双胍双联或三联口服糖尿病治疗的门诊患者的糖化血红蛋白变化进行了回顾性、观察性队列研究。
结果
加用第二种药物后，糖化血红蛋白下降的调整反应在 0.85%到 1.21%之间。加用第三种药物的反应较小（0.53%到 0.91%）。较高的基线糖化血红蛋白与更大的反应相关；磺酰脲类药物的有效性随时间下降；噻唑烷二酮类药物在肥胖患者和女性中更有效。
结论
观察性数据提供的结果与有限的可用随机糖尿病药物有效性数据定性一致，并将这些发现扩展到随机数据不可用的常见临床情况下。性别和 BMI 影响糖尿病药物联合治疗的比较效果。
相似文献
1
Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin.口服糖尿病药物联合治疗降低糖化血红蛋白的疗效比较。
J Comp Eff Res. 2014 Jan;3(1):29-39. doi: 10.2217/cer.13.87.
2
Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.门诊临床实践中曲格列酮对2型糖尿病的一级、二级、三级和四级治疗
Endocr Pract. 2000 Jan-Feb;6(1):20-5. doi: 10.4158/EP.6.1.20.
3
Summaries for patients: Oral drug treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.患者摘要：2型糖尿病的口服药物治疗：美国医师学会临床实践指南
Ann Intern Med. 2012 Feb 7;156(3):I36. doi: 10.7326/0003-4819-156-3-201202070-00004.
4
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.在单独使用二甲双胍或磺酰脲类药物控制不佳的 2 型糖尿病成人中，额外口服司美格鲁肽对比西格列汀对糖化血红蛋白的影响：PIONEER 3 随机临床试验。
JAMA. 2019 Apr 16;321(15):1466-1480. doi: 10.1001/jama.2019.2942.
5
Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.对于使用两种口服药物治疗血糖仍未得到控制的2型糖尿病患者，甘精胰岛素联合二甲双胍治疗而非甘精胰岛素联合磺脲类药物治疗能提供与三联口服联合治疗相似的血糖控制效果。
J Diabetes Complications. 2015 Nov-Dec;29(8):1266-71. doi: 10.1016/j.jdiacomp.2015.05.022. Epub 2015 Jun 5.
6
Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.罗格列酮口服复方制剂治疗德国2型糖尿病的成本效益
Pharmacoeconomics. 2006;24 Suppl 1:35-48. doi: 10.2165/00019053-200624001-00004.
7
How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?对于2型糖尿病患者，联合使用二甲双胍和磺脲类药物可以避免胰岛素治疗多长时间？
Endocr Pract. 2000 Jul-Aug;6(4):293-5. doi: 10.4158/EP.6.4.293.
8
Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.曲格列酮联合磺脲类药物加二甲双胍治疗可实现并维持有效的糖尿病控制。
Endocr Pract. 2000 Jul-Aug;6(4):305-10. doi: 10.4158/EP.6.4.305.
9
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.对于二甲双胍和噻唑烷二酮治疗控制不佳的2型糖尿病患者，使用格列美脲进行三联疗法：一项为期30周的随机、双盲、安慰剂对照、平行组研究的结果。
Clin Ther. 2005 Oct;27(10):1535-47. doi: 10.1016/j.clinthera.2005.10.017.
10
Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.2型糖尿病中的胰岛素：尽管基于替代终点的评估有限，但仍是一种有用的选择。
Prescrire Int. 2005 Oct;14(79):187-93.
引用本文的文献
1
Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.格列美脲、阿格列汀和阿格列汀-吡格列酮作为治疗不佳的 2 型糖尿病患者初始治疗药物的疗效比较：一项开放标签、多中心、随机、对照研究。
Diabetes Metab J. 2022 Sep;46(5):689-700. doi: 10.4093/dmj.2021.0183. Epub 2022 Mar 17.
2
Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA).糖尿病药物的安全性和作用模式与 5-氨基乙酰丙酸（5-ALA）的比较。
J Diabetes Res. 2019 Nov 6;2019:4267357. doi: 10.1155/2019/4267357. eCollection 2019.
3
AWRK6, a Novel GLP-1 Receptor Agonist, Attenuates Diabetes by Stimulating Insulin Secretion.AWRK6，一种新型 GLP-1 受体激动剂，通过刺激胰岛素分泌来减轻糖尿病。
Int J Mol Sci. 2018 Oct 7;19(10):3053. doi: 10.3390/ijms19103053.
4
Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.性别和 BMI 改变了磺酰脲类药物和噻唑烷二酮类药物在 2 型糖尿病中的获益和风险：使用常规临床和个体试验数据评估分层的框架。
Diabetes Care. 2018 Sep;41(9):1844-1853. doi: 10.2337/dc18-0344. Epub 2018 Aug 2.
5
Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial.利格列汀与伏格列波糖对2型糖尿病患者代谢指标的影响：一项随机、双盲、安慰剂对照试验。
BMC Pharmacol Toxicol. 2018 Jul 3;19(1):38. doi: 10.1186/s40360-018-0228-z.
6
Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin: Simulation Study of Power and Predictions Using Model-Based Analysis.葡萄糖耐量试验中不使用胰岛素时药物特征分析的意义：基于模型分析的效能和预测模拟研究。
CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):686-694. doi: 10.1002/psp4.12214. Epub 2017 Sep 25.
7
Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement.关于糖尿病药物相对疗效的观察性研究和临床试验结果显示出一致性。
J Clin Epidemiol. 2015 Feb;68(2):200-10. doi: 10.1016/j.jclinepi.2014.09.001. Epub 2014 Nov 26.
8
Sex differences in type 2 diabetes: focus on disease course and outcomes.2型糖尿病中的性别差异：关注疾病进程与结局。
Diabetes Metab Syndr Obes. 2014 Sep 16;7:409-20. doi: 10.2147/DMSO.S51301. eCollection 2014.
9
Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes.质子泵抑制剂不会损害糖尿病患者使用二甲双胍的疗效。
Br J Clin Pharmacol. 2015 Feb;79(2):330-6. doi: 10.1111/bcp.12506.
本文引用的文献
1
The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.糖尿病药物的心血管安全性——来自罗格列酮经验的见解。
N Engl J Med. 2013 Oct 3;369(14):1285-7. doi: 10.1056/NEJMp1309610. Epub 2013 Sep 2.
2
Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.我们仍需要吡格列酮来治疗2型糖尿病吗？2013年的风险效益评估。
Diabetes Care. 2013 Aug;36 Suppl 2(Suppl 2):S155-61. doi: 10.2337/dcS13-2031.
3
Interpreting adverse signals in diabetes drug development programs.解读糖尿病药物研发项目中的不良信号。
Diabetes Care. 2013 Jul;36(7):2098-106. doi: 10.2337/dc13-0182. Epub 2013 May 21.
4
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).糖尿病血糖降低方法的原理和设计：一项比较效果研究（GRADE）。
Diabetes Care. 2013 Aug;36(8):2254-61. doi: 10.2337/dc13-0356. Epub 2013 May 20.
5
AACE comprehensive diabetes management algorithm 2013.美国临床内分泌医师协会2013年综合糖尿病管理算法
Endocr Pract. 2013 Mar-Apr;19(2):327-36. doi: 10.4158/endp.19.2.a38267720403k242.
6
Standards of medical care in diabetes--2013.《糖尿病医疗护理标准——2013》
Diabetes Care. 2013 Jan;36 Suppl 1(Suppl 1):S11-66. doi: 10.2337/dc13-S011.
7
Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates.健康改善网络（THIN）数据库的可推广性：人口统计学、慢性病患病率和死亡率
Inform Prim Care. 2011;19(4):251-5. doi: 10.14236/jhi.v19i4.820.
8
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.吡格列酮的使用与 2 型糖尿病患者膀胱癌风险：巢式病例对照研究。
BMJ. 2012 May 30;344:e3645. doi: 10.1136/bmj.e3645.
9
Thiazolidinediones and PPARγ agonists: time for a reassessment.噻唑烷二酮类药物和过氧化物酶体增殖物激活受体 γ 激动剂：重新评估的时机。
Trends Endocrinol Metab. 2012 May;23(5):205-15. doi: 10.1016/j.tem.2012.03.001. Epub 2012 Apr 17.
10
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.《2 型糖尿病的口服药物治疗：美国医师学会临床实践指南》。
Ann Intern Med. 2012 Feb 7;156(3):218-31. doi: 10.7326/0003-4819-156-3-201202070-00011.
Zotero 插件